| Cellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells Reducing Triple-Negative Breast Cancer While Preserving Safety | 09/03 16:30 | globenewswire.com |
| Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid Tumors | 08/26 16:30 | globenewswire.com |
| Cellectis Appoints Dr. Adrian Kilcoyne as Chief Medical Officer | 08/07 02:00 | globenewswire.com |
| Cellectis Provides Financial Results for the Second Quarter 2024 | 08/06 16:30 | globenewswire.com |
| FDA Grants Orphan Drug Designation to Cellectis' CLLS52 (alemtuzumab) For ALL Treatment | 08/01 16:30 | globenewswire.com |
| FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis' UCART22 product candidate for Acute Lymphoblastic Leukemia (ALL) Treatment | 07/25 16:30 | globenewswire.com |
| Down -22.78% in 4 Weeks, Here's Why You Should You Buy the Dip in Cellectis (CLLS) | 07/10 10:37 | zacks.com |
| Cellectis Reports Results from Shareholders Meeting Held on June 28, 2024 | 06/28 16:30 | globenewswire.com |
| Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base Editing | 06/20 16:30 | globenewswire.com |
| Cellectis (CLLS) Upgraded to Buy: Here's Why | 06/18 13:01 | zacks.com |